Loading...
Market
Regulatory approval for Asahi Kasei's acquisition of Calliditas by end of 2024?
4
Asahi Kasei•Swedish•Calliditas Therapeutics AB•American Depositary Share•ADS•Sofinnova Partners•Amolyt Pharma•LimFlow•Calliditas Therapeutics
Resolution / Starting Odds
Yes • 50%
No • 50%
Regulatory announcements or official news
Story
Asahi Kasei to Acquire Calliditas Therapeutics for $1.1 Billion in $1.05b Offer
May 28, 2024, 08:27 AM
Asahi Kasei has announced its acquisition of Swedish drugmaker Calliditas Therapeutics AB for approximately $1.1 billion. The deal will see Asahi Kasei paying SEK 416, or about USD $39.37 in cash per American Depositary Share (ADS). This acquisition marks the third successful exit for Sofinnova Partners, following the recent exits of Amolyt Pharma and LimFlow. Calliditas Therapeutics, known for its focus on rare diseases, will be integrated into Asahi Kasei's expanding pharmaceutical portfolio. The acquisition offer was valued at $1.05 billion.
View original story
Similar markets
Increase over 10% • 33%
Decrease • 33%
Little to no change • 34%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
1-2 acquisitions • 33%
3-5 acquisitions • 33%
More than 5 acquisitions • 34%
Yes • 50%
No • 50%
